

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**AIM Vaccine Co., Ltd.**  
**艾美疫苗股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 06660)**

**VOLUNTARY ANNOUNCEMENT**  
**SUSPENSION CULTURE INFLUENZA VACCINE (MDCK CELLS) WITH**  
**NEW TECHNOLOGICAL ROUTE OBTAINED THE CLINICAL TRIAL**  
**APPROVAL**

This announcement is made by AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business developments of the Group.

The clinical trial approval for the Group’s suspension culture quadrivalent influenza vaccine (MDCK cells) with new technological route has been recently obtained from the National Medical Products Administration, which marks a new progress of the research and development of the vaccine. Currently, all influenza vaccines available on the domestic market are produced using chicken embryo technology. There have not been cell-based influenza vaccines approved for marketing. As a heavyweight key product, influenza vaccine (MDCK cells) is expected to become a new growth driver of the Group after its launch.

According to the estimation of the World Health Organization, about 1 billion people are infected with influenza virus every year, of which about 20%-30% of children and 5%-10% of adults suffer from seasonal influenza, which can cause 3 to 5 million cases of severe illnesses and 290,000 to 650,000 respiratory diseases-related deaths, seriously endangering human health. Influenza vaccination is the most cost-effective and effective measure to prevent influenza diseases and pandemic outbreaks. In 2023, the approved lot release volume of influenza vaccines was approximately 76.69 million doses in China, and China Insights Industry Consultancy Limited predicts that China’s influenza vaccine market will reach approximately RMB20 billion in 2030.

Compared with the traditional chicken embryo influenza split vaccine, the influenza vaccine (MDCK cells) developed by the Group has been significantly improved in terms of production quality and safety. The MDCK cells developed by the Group have the characteristics of easy cultivation, fast proliferation and susceptibility to influenza virus, etc. By large-scale cultivation of influenza virus in MDCK cells, it can achieve higher production volume, more stable production quality and lower production cost. Furthermore, this product has robust capability to withstand virus mutations, and does not contain ovalbumin, significantly reducing the risk of allergic reactions.

Compared with the influenza vaccines (MDCK cells) developed by other domestic manufacturers, we adopt the suspension culture method for cell culture, which can be cultivated in bioreactors at scale with low contamination risks and is conducive to large-scale industrial production. The launch of this product will be beneficial for enriching the Group's product lines, consolidating the Group's industry position and achieving sustainable and rapid growth of the Group's performance.

By order of the Board  
**AIM Vaccine Co., Ltd.**

**Mr. Yan ZHOU**

*Chairman of the Board, Executive Director and  
Chief Executive Officer*

Hong Kong, December 19, 2024

*As at the date of this announcement, the Board of the Company comprises Mr. Yan ZHOU, Mr. Xin ZHOU, Mr. Wen GUAN, Mr. Shaojun JIA and Mr. Jie ZHOU as executive directors; Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive directors; and Professor Ker Wei PEI, Mr. Hui OUYANG, Ms. Jie WEN and Mr. Xiaoguang GUO as independent non-executive directors.*